Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 225

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation

Open access
Kodali, Susheel, Hahn, Rebecca T., Eleid, Mackram F., Kipperman, Robert, Smith, Robert, Lim, D. Scott, Gray, William A., Narang, Akhil, Pislaru, Sorin V., Koulogiannis, Konstantinos, Grayburn, Paul, Fowler, Dale, Hawthorne, Katie, Dahou, Abdellaziz, Deo, Shekhar H., Vandrangi, Prashanthi, Deuschl, Florian, Mack, Michael J., Leon, Martin B., Feldman, Ted, Davidson, Charles J. · 2021 · Journal of the American College of Cardiology

Abstract

BACKGROUND Tricuspid regurgitation (TR) is a prevalent disease with limited treatment options. OBJECTIVES This is the first 30-day report of the U.S. single-arm, multicenter, prospective CLASP TR early feasibility study of the PASCAL transcatheter valve repair system in the treatment of TR. METHODS Patients with symptomatic TR despite optimal medical therapy, reviewed by the local heart team and central screening committee, were eligible for the study. Data were collected at baseline, discharge, and the 30-day follow-up and were reviewed by an independent clinical events committee and echocardiographic core laboratory. Feasibility endpoints included safety (composite major adverse event [MAE] rate), echocardiographic, clinical, and functional endpoints. RESULTS Of the 34 patients enrolled in the study, the mean age was 76 years, 53% were women, the mean Society of Thoracic Surgeons score was 7.3%, 88% had atrial fibrillation/flutter, 97% had severe or greater TR, and 79% had New York Heart Association (NYHA) functional class III/IV symptoms. Twenty-nine patients (85%) received implants; at 30 days, 85% of them achieved a TR severity reduction of at least 1 grade, with 52% with moderate or less TR (p < 0.001). The MAE rate was 5.9%, and none of the patients experienced cardiovascular mortality, stroke, myocardial infarction, renal complication, or reintervention. Eighty-nine percent of the patients improved to NYHA functional class I/II (p < 0.001), the mean 6-min walk distance improved by 71 m (p < 0.001), and the mean Kansas City Cardiomyopathy Questionnaire score improved by 15 points (p < 0.001). CONCLUSIONS In this early experience, the repair system performed as intended, with substantial TR reduction, favorable safety results with a low MAE rate, no mortality or reintervention, and significant improvements in functional status, exercise capacity, and quality of life. (Edwards CLASP TR EFS [CLASP TR EFS]; NCT03745313).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.11.047

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 225

Metadata

Authors
Kodali, S., Hahn, R. T., Eleid, M. F., Kipperman, R., Smith, R., Lim, D. S., Gray, W. A., Narang, A., Pislaru, S. V., Koulogiannis, K., Grayburn, P., Fowler, D., Hawthorne, K., Dahou, A., Deo, S. H., Vandrangi, P., Deuschl, F., Mack, M. J., Leon, M. B., Feldman, T., & Davidson, C. J.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2021-02
Volume
77
Issue
4
Pages
345-356
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3125953136
Cited by
225
References
1
FWCI
27.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation. https://app.cochat.ai/papers/10.1016/j.jacc.2020.11.047
The paper
Kodali, S., Hahn, R. T., Eleid, M. F., Kipperman, R., Smith, R., Lim, D. S., Gray, W. A., Narang, A., Pislaru, S. V., Koulogiannis, K., Grayburn, P., Fowler, D., Hawthorne, K., Dahou, A., Deo, S. H., Vandrangi, P., Deuschl, F., Mack, M. J., Leon, M. B., . . . Davidson, C. J. (2021). Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2020.11.047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.